Treatment of behavioural disturbances in Parkinson’s disease

Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: Histological, neurochemical, motor and memory alterations

“…Even non-demented PD patients have been reported to present visuospatial working memory deficits (Dubois and Pillon, 1997;Owen et al, 1997;Valldeoriola et al, 1997;Stebbins et al, 1999;Hodgson et al, 1999;Carbon and Marie, 2003;Costa et al, 2001;Crucian and Okun, 2003;Lewis et al, 2003) and habit learning deficits (Knowlton et al, 1996;Rieger and Markowitsch, 1996;Fama et al, 2000). In the present study, we showed that MPTP-and 6-OHDAlesioned rats reproduced these memory impairments.…”

Psychiatric side-effects of medications: recent developments

“…MAO-B and COMT inhibitors might enhance mood, but there are no systematic trials to support their use as antidepressants (Tiffani & Cummings, 1998). Most antidepressants can be used to treat depression in Parkinson's disease although there are isolated case reports of worsened parkinsonism with SSRIs (Valldeoriola et al, 1997).…”

Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies

“…The cholinesterase inhibitors, atypical antipsychotics and psychostimulants can be considered for management of hallucinations, delusions and apathy [79][80][81][82]. The following atypical antipsychotics can be considered: clozapine [83][84][85], risperidone [86,87], olanzapine [88,89] and quetiapine [85,90]. A phenomenon known as 'neuroleptic sensitivity' can occur with exposure to even small doses of haloperidol, chlorpromazine and other conventional neuroleptics, and these agents are now strongly discouraged [91].…”